Hemogen, a subsidiary company of BGI Group, adheres to the vision of BGI - "Omics for All". Supported by the strong scientific research capabilities of BGI-Research and BGI Group's channel influence in the medical and health science field, Hemogen is committed to the treatment of hemoglobin diseases and to "Create A Thalassemia Free World Together".